MBMaria Beletskaya

Maria Beletskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Beletskaya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MANIFESTATION OF CHRONIC INFLAMMATORY COMPONENTS IN METABOLIC SYNDROME USING THE EXAMPLE OF CHANGES IN THE PROINFLAMMATORY ACTIVITY OF MONOCYTES/MACROPHAGES IN AN EXPERIMENTAL CELL MODEL

    by V.V. Malashchenko, O.G. Khaziakhmatova, K.A. Yurova, M.M. Bograya, N.D. Gazatova, M.A. Vulf, N.M. Todosenko, O.B. Melashchenko, M.A. Beletskaya, L.S. Litvinova

    Metabolic syndrome (MS) is one of the most common and socially significant problems of the 21st century. Its progression contributes to the onset and development of a number of serious comorbidities, such as insulin resistance/diabetes mellitus, liver and kidney damage, cardiovascular pathologies. Such a broad profile of comorbidities is due to the development of systemic chronic inflammation. The most important cells involved in this process are tissue-resident macrophages. We hypothesise that the negative effects of proinflammatory factors in MS in general may also affect the monocyte-macrophage component of the immune system. The aim of the study is to identify differences in monocyte/macrophage activity in individuals with MS compared to conditionally healthy donors. Materials and methods. Monocyte/macrophage cultures obtained from the whole blood of individuals with MS using the immunomagnetic separation method were used for the study. An experimental in vitro model was developed to determine the sensitivity of immune cells to a proinflammatory stimulus (LPS) as assessed by the production of the cytokines MCP-1, TNF-α, IL-1β, IL-6, IL-8 and IL-10 by the cells. Results and conclusions. A decrease in the activity of peripheral blood monocytes is observed in MS; they show a decreased basal secretion of cytokines, which may indicate a suppression of their cytokine-producing activity due to a high concentration of proinflammatory factors in the circulation in MS. For IL-6 and IL-10, but not for other cytokines studied, an additional increase in LPS-induced secretion by monocytes in MS patients was demonstrated, which could be a consequence of both the «enrichment» of the monocyte subpopulation in the peripheral blood with «intermediate» and «non-classical» monocytes and the potential suppressor activity of IL-6. The correct formation of target groups plays an important role in the in vitro investigation of monocyte/macrophage activity in patients with MS. In particular, grouping MS patients by obesity level (BMI) could be more informative than the option based on grouping data by MS components.

  • Open Access

    Adipocyte- and Monocyte-Mediated Vicious Circle of Inflammation and Obesity (Review of Cellular and Molecular Mechanisms)

    by Natalia Todosenko, Olga Khaziakhmatova, Vladimir Malashchenko, Kristina Yurova, Maria Bograya, Maria Beletskaya, Maria Vulf, Larisa Mikhailova, Anastasia Minchenko, Irina Soroko, et al.

    Monocytes play a key role in the development of metabolic syndrome, and especially obesity. Given the complex features of their development from progenitor cells, whose regulation is mediated by their interactions with bone marrow adipocytes, the importance of a detailed study of the heterogeneous composition of monocytes at the molecular and systemic levels becomes clear. Research argues for monocytes as indicators of changes in the body’s metabolism and the possibility of developing therapeutic strategies to combat obesity and components of metabolic syndrome based on manipulations of the monocyte compound of the immune response. An in-depth study of the heterogeneity of bone-marrow-derived monocytes and adipocytes could provide answers to many questions about the pathogenesis of obesity and reveal their therapeutic potential.


  • Open Access

    Mitochondrial Dysfunction Associated with mtDNA in Metabolic Syndrome and Obesity

    by Natalia Todosenko, Olga Khaziakhmatova, Vladimir Malashchenko, Kristina Yurova, Maria Bograya, Maria Beletskaya, Maria Vulf, Natalia Gazatova, Larisa Litvinova

    Metabolic syndrome (MetS) is a precursor to the major health diseases associated with high mortality in industrialized countries: cardiovascular disease and diabetes. An important component of the pathogenesis of the metabolic syndrome is mitochondrial dysfunction, which is associated with tissue hypoxia, disruption of mitochondrial integrity, increased production of reactive oxygen species, and a decrease in ATP, leading to a chronic inflammatory state that affects tissues and organ systems. The mitochondrial AAA + protease Lon (Lonp1) has a broad spectrum of activities. In addition to its classical function (degradation of misfolded or damaged proteins), enzymatic activity (proteolysis, chaperone activity, mitochondrial DNA (mtDNA)binding) has been demonstrated. At the same time, the spectrum of Lonp1 activity extends to the regulation of cellular processes inside mitochondria, as well as outside mitochondria (nuclear localization). This mitochondrial protease with enzymatic activity may be a promising molecular target for the development of targeted therapy for MetS and its components. The aim of this review is to elucidate the role of mtDNA in the pathogenesis of metabolic syndrome and its components as a key component of mitochondrial dysfunction and to describe the promising and little-studied AAA + LonP1 protease as a potential target in metabolic disorders.